表紙
市場調査レポート

Zydus Cadila Healthcare Limited - 製品パイプライン分析

Zydus Cadila Healthcare Limited - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 224567
出版日 ページ情報 英文 86 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
Zydus Cadila Healthcare Limited - 製品パイプライン分析 Zydus Cadila Healthcare Limited - Product Pipeline Review - 2015
出版日: 2015年09月30日 ページ情報: 英文 86 Pages
概要

Zydus Cadila Healthcare Limited は、医薬品有効成分(API)、製剤、薬用化粧品、動物薬などの製品群で構成する幅広い事業を、開発から販売まで一貫して行っている世界的な製薬会社です。例えば、胃腸、心血管、婦人科系疾患、呼吸器系、疼痛管理、中枢神経系、抗感染症、癌、神経症、皮膚病、腎臓病関連の疾患など様々な治療への応用を対象とした製品を扱っています。

当レポートでは、Zydus Cadila Healthcare Limitedにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Zydus Cadila Healthcare Limitedの基本情報

Zydus Cadila Healthcare Limitedの概要

  • 主要情報
  • 企業情報

Zydus Cadila Healthcare Limited:R&Dの概要

  • 主な治療範囲

Zydus Cadila Healthcare Limited:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ

Zydus Cadila Healthcare Limited:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • IND/CTA Filed Products/Combination Treatment Modalities
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Zydus Cadila Healthcare Limited:開発段階が不明のパイプライン製品

  • 開発段階が不明の製品/併用療法モダリティ

Zydus Cadila Healthcare Limited:薬剤プロファイル

  • interferon beta-1b
  • saroglitazar
  • Vaccine for Live Measles, Mumps and Rubella
  • ZYH-7
  • ZYOG-1
  • PEG-EPO
  • Rabimabs Vaccine
  • Diptheria Tetanus Pertussis And Haemophilus Type B Conjugate Vaccine
  • Haemophilus Influenzae Type B Conjugated Vaccine
  • Live Attenuated Vaccine for Mumps
  • Live Attenuated Vaccine for Rubella
  • rituximab biosimilar
  • Tetanus Vaccine
  • Toxoid Vaccine for Diptheria and Tetanus
  • Vaccine for Diptheria, Tetanus and Pertussis
  • ZYD-1
  • ZYDPLA-1
  • ZYG-19
  • ZYGK-1
  • ZYPH-0907
  • ZYT-1
  • MAb-3
  • MAb-4
  • Biosimilar 4 for Acute Myocardial Infarction and Infertility
  • Drug for Atherosclerotic Plaque
  • ZYGL-241
  • Biosimilar 1 for Nephrology
  • Biosimilar 2 for Diabetes and Rheumatoid Arthritis
  • Biosimilar 3 for Rheumatoid Arthritis and Acute Myocardial Infarction
  • Biosimilar 5 for Infertility
  • Biosimilar 6 for Infertility
  • Biosimilar 7 for Infertility and Oncology
  • MAB-6
  • MAb-1
  • MAb-2

Zydus Cadila Healthcare Limited:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Zydus Cadila Healthcare Limited:最近のパイプライン動向

Zydus Cadila Healthcare Limited:休止中のプロジェクト

Zydus Cadila Healthcare Limited:企業発表

Zydus Cadila Healthcare Limited:本社と子会社の所在地

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07627CDB

Summary

Global Markets Direct's, 'Zydus Cadila Healthcare Limited - Product Pipeline Review - 2015', provides an overview of the Zydus Cadila Healthcare Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Zydus Cadila Healthcare Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Zydus Cadila Healthcare Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Zydus Cadila Healthcare Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Zydus Cadila Healthcare Limited's pipeline products

Reasons to buy

  • Evaluate Zydus Cadila Healthcare Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Zydus Cadila Healthcare Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Zydus Cadila Healthcare Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Zydus Cadila Healthcare Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Zydus Cadila Healthcare Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Zydus Cadila Healthcare Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Zydus Cadila Healthcare Limited Snapshot
    • Zydus Cadila Healthcare Limited Overview
    • Key Information
    • Key Facts
  • Zydus Cadila Healthcare Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Zydus Cadila Healthcare Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Zydus Cadila Healthcare Limited - Pipeline Products Glance
    • Zydus Cadila Healthcare Limited - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Zydus Cadila Healthcare Limited - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Zydus Cadila Healthcare Limited - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • Zydus Cadila Healthcare Limited - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Zydus Cadila Healthcare Limited - Drug Profiles
    • interferon beta-1b
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MAb-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • measles vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • saroglitazar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tetanus vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • measles + mumps + rubella vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZYH-7
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PEG-EPO
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Rabimabs
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • leishmaniasis vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rituximab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZYAN-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZYDPLA-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZYG-19
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZYGK-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZYT-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar 4 for Acute Myocardial Infarction, Infertility and Thrombosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar 1 for Nephrology and Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar 2 for Diabetes and Rheumatoid Arthritis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar 3 for Rheumatoid Arthritis, Acute Myocardial Infarction and Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar 5 for Infertility
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar 6 for Infertility
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar 7 for Infertility and Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar 8 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar for Immunology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • diphtheria + tetanus + pertussis (whole-cell) + haemophilus influenzae [serotype B] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • diphtheria + tetanus + pertussis (whole-cell) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • diphtheria + tetanus vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • haemophilus influenzae [serotype B] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hepatitis A vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hepatitis B vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hepatitis E vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Japanese encephalitis vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MAb-6
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MAb-7
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MAb-8
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • malaria vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Cervical Cancer and Genital Warts
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • typhoid vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MAb-2
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MAb-3
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MAb-4
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Zydus Cadila Healthcare Limited - Pipeline Analysis
    • Zydus Cadila Healthcare Limited - Pipeline Products by Target
    • Zydus Cadila Healthcare Limited - Pipeline Products by Route of Administration
    • Zydus Cadila Healthcare Limited - Pipeline Products by Molecule Type
    • Zydus Cadila Healthcare Limited - Pipeline Products by Mechanism of Action
  • Zydus Cadila Healthcare Limited - Recent Pipeline Updates
  • Zydus Cadila Healthcare Limited - Dormant Projects
  • Zydus Cadila Healthcare Limited - Company Statement
  • Zydus Cadila Healthcare Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Zydus Cadila Healthcare Limited, Key Information
  • Zydus Cadila Healthcare Limited, Key Facts
  • Zydus Cadila Healthcare Limited - Pipeline by Indication, 2015
  • Zydus Cadila Healthcare Limited - Pipeline by Stage of Development, 2015
  • Zydus Cadila Healthcare Limited - Monotherapy Products in Pipeline, 2015
  • Zydus Cadila Healthcare Limited - Combination Treatment Modalities in Pipeline, 2015
  • Zydus Cadila Healthcare Limited - Partnered Products in Pipeline, 2015
  • Zydus Cadila Healthcare Limited - Partnered Products/ Combination Treatment Modalities, 2015
  • Zydus Cadila Healthcare Limited - Pre-Registration, 2015
  • Zydus Cadila Healthcare Limited - Phase III, 2015
  • Zydus Cadila Healthcare Limited - Phase II, 2015
  • Zydus Cadila Healthcare Limited - Phase I, 2015
  • Zydus Cadila Healthcare Limited - IND/CTA Filed, 2015
  • Zydus Cadila Healthcare Limited - Preclinical, 2015
  • Zydus Cadila Healthcare Limited - Discovery, 2015
  • Zydus Cadila Healthcare Limited - Unknown, 2015
  • Zydus Cadila Healthcare Limited - Pipeline by Target, 2015
  • Zydus Cadila Healthcare Limited - Pipeline by Route of Administration, 2015
  • Zydus Cadila Healthcare Limited - Pipeline by Molecule Type, 2015
  • Zydus Cadila Healthcare Limited - Pipeline Products by Mechanism of Action, 2015
  • Zydus Cadila Healthcare Limited - Recent Pipeline Updates, 2015
  • Zydus Cadila Healthcare Limited - Dormant Developmental Projects,2015
  • Zydus Cadila Healthcare Limited, Subsidiaries

List of Figures

  • Zydus Cadila Healthcare Limited - Pipeline by Top 10 Indication, 2015
  • Zydus Cadila Healthcare Limited - Pipeline by Stage of Development, 2015
  • Zydus Cadila Healthcare Limited - Monotherapy Products in Pipeline, 2015
  • Zydus Cadila Healthcare Limited - Combination Treatment Modalities in Pipeline, 2015
  • Zydus Cadila Healthcare Limited - Pipeline by Top 10 Target, 2015
  • Zydus Cadila Healthcare Limited - Pipeline by Top 10 Route of Administration, 2015
  • Zydus Cadila Healthcare Limited - Pipeline by Top 10 Molecule Type, 2015
  • Zydus Cadila Healthcare Limited - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top